Abbott India Limited
Abbott India Limited (ABBOTINDIA.BO) Stock Competitors & Peer Comparison
See (ABBOTINDIA.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABBOTINDIA.BO | ₹26,275.30 | -0.82% | 558.3B | 36.98 | ₹710.49 | +1.81% |
| CIPLA.BO | ₹1,193.40 | -0.21% | 964B | 21.23 | ₹56.20 | +1.34% |
| CIPLA.NS | ₹1,192.40 | -0.29% | 963.2B | 21.19 | ₹56.28 | +1.34% |
| ABBOTINDIA.NS | ₹26,285.00 | -0.77% | 558.5B | 36.63 | ₹717.58 | +1.81% |
| GLAXO.NS | ₹2,311.50 | -0.76% | 391.6B | 38.31 | ₹60.33 | +2.34% |
| GLAXO.BO | ₹2,310.45 | -0.60% | 391.4B | 41.04 | ₹56.30 | +2.34% |
| GLAND.BO | ₹1,689.95 | -0.98% | 278.4B | 32.90 | ₹51.37 | +1.07% |
| GLAND.NS | ₹1,688.60 | -1.02% | 278.2B | 32.79 | ₹51.50 | +1.07% |
| PFIZER.NS | ₹4,887.10 | +0.70% | 223.6B | 26.22 | ₹186.36 | +3.38% |
| PFIZER.BO | ₹4,881.95 | +0.62% | 223.3B | 26.63 | ₹183.33 | +3.38% |
Stock Comparison
ABBOTINDIA.BO vs CIPLA.BO Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, CIPLA.BO has a market cap of 964B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while CIPLA.BO trades at ₹1,193.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas CIPLA.BO's P/E ratio is 21.23. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to CIPLA.BO's ROE of +0.15%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to CIPLA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check CIPLA.BO's competition here
ABBOTINDIA.BO vs CIPLA.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, CIPLA.NS has a market cap of 963.2B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while CIPLA.NS trades at ₹1,192.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas CIPLA.NS's P/E ratio is 21.19. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to CIPLA.NS's ROE of +0.15%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to CIPLA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check CIPLA.NS's competition here
ABBOTINDIA.BO vs ABBOTINDIA.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, ABBOTINDIA.NS has a market cap of 558.5B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while ABBOTINDIA.NS trades at ₹26,285.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas ABBOTINDIA.NS's P/E ratio is 36.63. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to ABBOTINDIA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check ABBOTINDIA.NS's competition here
ABBOTINDIA.BO vs GLAXO.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, GLAXO.NS has a market cap of 391.6B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while GLAXO.NS trades at ₹2,311.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas GLAXO.NS's P/E ratio is 38.31. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to GLAXO.NS's ROE of +0.56%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to GLAXO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check GLAXO.NS's competition here
ABBOTINDIA.BO vs GLAXO.BO Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, GLAXO.BO has a market cap of 391.4B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while GLAXO.BO trades at ₹2,310.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas GLAXO.BO's P/E ratio is 41.04. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to GLAXO.BO's ROE of +0.56%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to GLAXO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check GLAXO.BO's competition here
ABBOTINDIA.BO vs GLAND.BO Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, GLAND.BO has a market cap of 278.4B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while GLAND.BO trades at ₹1,689.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas GLAND.BO's P/E ratio is 32.90. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to GLAND.BO's ROE of +0.09%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to GLAND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check GLAND.BO's competition here
ABBOTINDIA.BO vs GLAND.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, GLAND.NS has a market cap of 278.2B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while GLAND.NS trades at ₹1,688.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas GLAND.NS's P/E ratio is 32.79. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to GLAND.NS's ROE of +0.09%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to GLAND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check GLAND.NS's competition here
ABBOTINDIA.BO vs PFIZER.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, PFIZER.NS has a market cap of 223.6B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while PFIZER.NS trades at ₹4,887.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas PFIZER.NS's P/E ratio is 26.22. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to PFIZER.NS's ROE of +0.21%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to PFIZER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check PFIZER.NS's competition here
ABBOTINDIA.BO vs PFIZER.BO Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, PFIZER.BO has a market cap of 223.3B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while PFIZER.BO trades at ₹4,881.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas PFIZER.BO's P/E ratio is 26.63. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to PFIZER.BO's ROE of +0.21%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to PFIZER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check PFIZER.BO's competition here
ABBOTINDIA.BO vs SANOFICONR.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, SANOFICONR.NS has a market cap of 105.4B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while SANOFICONR.NS trades at ₹4,578.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas SANOFICONR.NS's P/E ratio is 43.89. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to SANOFICONR.NS's ROE of +0.79%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to SANOFICONR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check SANOFICONR.NS's competition here
ABBOTINDIA.BO vs MARKSANS.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, MARKSANS.NS has a market cap of 76.2B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while MARKSANS.NS trades at ₹168.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas MARKSANS.NS's P/E ratio is 21.15. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to MARKSANS.NS's ROE of +0.14%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to MARKSANS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check MARKSANS.NS's competition here
ABBOTINDIA.BO vs MARKSANS.BO Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, MARKSANS.BO has a market cap of 76.2B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while MARKSANS.BO trades at ₹168.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas MARKSANS.BO's P/E ratio is 21.67. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to MARKSANS.BO's ROE of +0.14%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to MARKSANS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check MARKSANS.BO's competition here
ABBOTINDIA.BO vs SANOFI.BO Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, SANOFI.BO has a market cap of 75.2B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while SANOFI.BO trades at ₹3,265.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas SANOFI.BO's P/E ratio is 23.03. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to SANOFI.BO's ROE of +0.37%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to SANOFI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check SANOFI.BO's competition here
ABBOTINDIA.BO vs SANOFI.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, SANOFI.NS has a market cap of 75.2B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while SANOFI.NS trades at ₹3,265.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas SANOFI.NS's P/E ratio is 23.01. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to SANOFI.NS's ROE of +0.37%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to SANOFI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check SANOFI.NS's competition here
ABBOTINDIA.BO vs SMSPHARMA.BO Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, SMSPHARMA.BO has a market cap of 36.4B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while SMSPHARMA.BO trades at ₹388.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas SMSPHARMA.BO's P/E ratio is 38.72. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to SMSPHARMA.BO's ROE of +0.14%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to SMSPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check SMSPHARMA.BO's competition here
ABBOTINDIA.BO vs SMSPHARMA.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, SMSPHARMA.NS has a market cap of 36.4B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while SMSPHARMA.NS trades at ₹388.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas SMSPHARMA.NS's P/E ratio is 38.63. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to SMSPHARMA.NS's ROE of +0.14%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to SMSPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check SMSPHARMA.NS's competition here
ABBOTINDIA.BO vs SENORES.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, SENORES.NS has a market cap of 36.1B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while SENORES.NS trades at ₹784.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas SENORES.NS's P/E ratio is 30.54. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to SENORES.NS's ROE of +0.13%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to SENORES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check SENORES.NS's competition here
ABBOTINDIA.BO vs NGLFINE.BO Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, NGLFINE.BO has a market cap of 13.3B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while NGLFINE.BO trades at ₹2,146.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas NGLFINE.BO's P/E ratio is 37.49. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to NGLFINE.BO's ROE of +0.12%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to NGLFINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check NGLFINE.BO's competition here
ABBOTINDIA.BO vs NGLFINE.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, NGLFINE.NS has a market cap of 13.2B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while NGLFINE.NS trades at ₹2,132.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas NGLFINE.NS's P/E ratio is 37.26. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to NGLFINE.NS's ROE of +0.12%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to NGLFINE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check NGLFINE.NS's competition here
ABBOTINDIA.BO vs TTKHLTCARE.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, TTKHLTCARE.NS has a market cap of 11.2B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while TTKHLTCARE.NS trades at ₹789.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas TTKHLTCARE.NS's P/E ratio is 18.55. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to TTKHLTCARE.NS's ROE of +0.06%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to TTKHLTCARE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check TTKHLTCARE.NS's competition here
ABBOTINDIA.BO vs KOPRAN.BO Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, KOPRAN.BO has a market cap of 5.8B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while KOPRAN.BO trades at ₹120.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas KOPRAN.BO's P/E ratio is 35.34. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to KOPRAN.BO's ROE of +0.03%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to KOPRAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check KOPRAN.BO's competition here
ABBOTINDIA.BO vs KOPRAN.NS Comparison April 2026
ABBOTINDIA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.BO stands at 558.3B. In comparison, KOPRAN.NS has a market cap of 5.8B. Regarding current trading prices, ABBOTINDIA.BO is priced at ₹26,275.30, while KOPRAN.NS trades at ₹119.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.BO currently has a P/E ratio of 36.98, whereas KOPRAN.NS's P/E ratio is 35.08. In terms of profitability, ABBOTINDIA.BO's ROE is +0.38%, compared to KOPRAN.NS's ROE of +0.03%. Regarding short-term risk, ABBOTINDIA.BO is less volatile compared to KOPRAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.BO.Check KOPRAN.NS's competition here